Binocular metamorphopsia in patients with branch retinal vein occlusion: a multi-center study.
Binocular metamorphopsia
Branch retinal vein occlusion
M-CHARTS
Macular edema
Metamorphopsia
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
21
07
2022
accepted:
22
04
2023
medline:
4
8
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
The pathology of branch retinal vein occlusion (BRVO), a retinal circulatory disease, is related to monocular metamorphopsia-related vision impairment of the affected eyes, but the association of binocular metamorphopsia in such patients is unclear. This study aimed to examine the frequency of binocular metamorphopsia and its association with the clinical characteristics of patients with BRVO. A total of 87 patients who were treated for BRVO-associated macular edema (ME) were included in this study. At baseline and 1 and 3 months after the initiation of anti-vascular endothelial growth factor (VEGF) treatment, we quantified metamorphopsia in the affected eyes and binocular metamorphopsia using the M-CHARTS At baseline, 53 and 7 patients had metamorphopsia in the affected eyes and binocular metamorphopsia, respectively. Although the visual acuity improved significantly after the initiation of anti-VEGF treatment, the mean M-CHARTS score in the affected eyes did not change from the baseline score. At 3 months, 9 patients showed binocular metamorphopsia; it was significantly associated with metamorphopsia in the affected eyes with a 95% confidence interval of 0.021-0.122 (β = 0.306, p = 0.006). Metamorphopsia in the affected eyes can cause binocular metamorphopsia in patients with BRVO-ME.
Identifiants
pubmed: 37227617
doi: 10.1007/s10792-023-02731-0
pii: 10.1007/s10792-023-02731-0
pmc: PMC10400688
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Angiogenesis Inhibitors
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3279-3286Informations de copyright
© 2023. The Author(s).
Références
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2961-6
pubmed: 16043872
Retina. 2018 Aug;38(8):1581-1587
pubmed: 28614133
Invest Ophthalmol Vis Sci. 2012 Jun 14;53(7):3592-7
pubmed: 22589432
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3835-3841
pubmed: 31529080
Ophthalmology. 2014 May;121(5):1059-66
pubmed: 24424249
Ophthalmology. 2009 Sep;116(9):1788-93
pubmed: 19643494
JAMA. 2017 May 23;317(20):2072-2087
pubmed: 28492910
Sci Rep. 2021 Feb 24;11(1):4454
pubmed: 33627734
Clin Ophthalmol. 2015 Feb 04;9:225-33
pubmed: 25678770
Acta Ophthalmol. 2015 Dec;93(8):e649-53
pubmed: 25899144
Transl Vis Sci Technol. 2021 Mar 1;10(3):31
pubmed: 34003964
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3327-34
pubmed: 11006221
PLoS One. 2016 Apr 28;11(4):e0153817
pubmed: 27123642
Br J Ophthalmol. 2006 May;90(5):627-39
pubmed: 16622095
Ophthalmology. 2016 Feb;123(2):330-336
pubmed: 26522708
Nippon Ganka Gakkai Zasshi. 2007 Apr;111(4):331-5
pubmed: 17461039
PLoS One. 2018 Sep 20;13(9):e0204015
pubmed: 30235264
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009510
pubmed: 23440840
Br J Ophthalmol. 2022 Feb;106(2):241-245
pubmed: 33172863
Eye (Lond). 2022 Feb;36(2):457-462
pubmed: 33707764
Ophthalmology. 2012 Oct;119(10):2108-18
pubmed: 22817833
Retina. 2011 Nov;31(10):2102-8
pubmed: 21734622
Ophthalmic Physiol Opt. 2020 Nov;40(6):778-789
pubmed: 32885878
BMJ Open. 2019 May 28;9(5):e022031
pubmed: 31142516
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2191-2196
pubmed: 27169934
Ophthalmology. 2012 Apr;119(4):802-9
pubmed: 22301066
Arch Ophthalmol. 2008 Apr;126(4):513-8
pubmed: 18413521